A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19
A small, randomized trial involving 30 patients in Shanghai reported on outcomes in patients treated with 400 mg of hydroxychloroquine daily for 5 days, as compared with a control group in which patients received “conventional treatment only.” This trial showed that by day 7, a total of 86% of the patients in the hydroxychloroquine-treated group and 93% of those in the control group had negative results on viral throat swabs.
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19
Hydroxychloroquine as Prophylactic Treatment for COVID-19
Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial
Observational Study of Hydroxychloroquine in Hospitalized Patients with COVID-19
Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis
Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial